drugset / Trial / NCT00651287

A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension

NCT00651287

Phase 4 Completed 200 enrolled Pfizer
Parallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the response rate for the therapeutic goal (diastolic blood pressure (BP) less than 90 mmHg and systolic BP less than 140 mmHg) at Week 6 for quinapril 20 mg and at Week 12 for quinapril 20 mg, quinapril 40 mg, and quinapril 20 mg plus hydrochlorothiazide 12.5 mg; and to determine the mean decrease in diastolic and systolic BP measurements and the change in heart rate at Week 6 and Week 12 compared with baseline.

Timeline

Start
2002-12
Primary completion
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydrochlorothiazide Unknown 12.5 mg
Comparator Quinapril Small molecule 20 mg Oral
Comparator Quinapril Small molecule 40 mg Oral

Indications